Kristian Helin is Chair of the Cell Biology Program, the Enid A. Haupt Chair in Cell Biology and the Director of Center for Epigenetics Research at Memorial Sloan Kettering Cancer Center. Dr. Helin is also a Professor at University of Copenhagen. He obtained a MSc in Chemical Engineering from the Technical University of Denmark and a PhD from University of Copenhagen. He was a research fellow at Harvard Medical School, started his own research group at the Danish Cancer Society in 1994 and became subsequently a founding member of the Dept of Experimental Oncology at the European Institute of Oncology in Milan, Italy. From 2003-2018 he was the founding director of the Biotech Research and Innovation at University of Copenhagen. The Helin laboratory has made several seminal discoveries in the field of cell cycle control, epigenetics and cancer.
In addition to providing novel insights into mechanisms regulating transcription, stem cell identity and differentiation, the work in Prof Helin’s lab has led to the establishment of a biotech company EpiTherapeutics, which in 2015 was sold to Gilead Inc. Dr. Helin is an elected member of European Molecular Biology Organisation (EMBO) and the Royal Danish Academy of Science and Letters. He has received several prestigious awards for outstanding biomedical research and serves in several editorial boards, committees of advisory boards and grant committees.